Overview

Targeting IL-17A for Treatment-Resistant Depression

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).

Phase:

Phase 2

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Treatments:

Ixekizumab